Full text not available from this repository.
Thanks to newborn screening and early dietary therapy, individuals with PKU no longer experience intellectual disability (mental retardation). Nevertheless, many do not achieve their full potential. The establishment of uniform guidelines and improved management for PKU can lead to optimal outcomes in this metabolic disorder. Two new approaches are currently available for the treatment of PKU in some patients:- The use of tetrahydrobiopterin (BH4; sapropterin) in individuals with PKU with certain mutations of the phenylalanine hydroxylase gene.- Supplementation with large neutral amino acids (LNAA) other than phenylalanine.Further approaches, such as recombinant phenylalanine ammonia lyase (PAL), which degrades phenylalanine, and gene therapy, using viral or non-viral vectors to correct murine PKU, are at the experimental stage.In this textbook past, present, and future efforts related to PKU and BH4 deficiencies are discussed. The reviews and scientific contributions in this book provide professionals, the patients and their families to understand PKU within a biochemical, neurological and psychosocial context.
|Item Type:||Edited Scientific Work|
|Communities & Collections:||04 Faculty of Medicine > University Children's Hospital Zurich > Medical Clinic|
|DDC:||610 Medicine & health|
|Deposited On:||06 Jan 2011 13:57|
|Last Modified:||04 Apr 2012 13:33|
|Publisher:||UNI-MED Verlag AG|
|Number of Pages:||77|
|Related URLs:||http://www.uni-med.de/kinderheilkunde_phenylketonuria_and_bh4_deficiencies,pid,475,rid,25,produktdetail.html (Publisher)|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page